drugset / Trial / NCT02515097

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

NCT02515097

Phase 3 Completed 213 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).

Timeline

Start
2015-11-05
Primary completion
2017-03-15
Completion
2017-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject halobetasol propionate Small molecule 0.01 % Topical

Indications